Faithward Advisors LLC Acquires 37,688 Shares of Bristol Myers Squibb Company $BMY

Faithward Advisors LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 781.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,512 shares of the biopharmaceutical company’s stock after purchasing an additional 37,688 shares during the period. Faithward Advisors LLC’s holdings in Bristol Myers Squibb were worth $2,578,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BMY. Brave Asset Management Inc. grew its stake in Bristol Myers Squibb by 16.8% during the first quarter. Brave Asset Management Inc. now owns 5,140 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 740 shares in the last quarter. Cidel Asset Management Inc. increased its holdings in shares of Bristol Myers Squibb by 20.4% in the first quarter. Cidel Asset Management Inc. now owns 32,697 shares of the biopharmaceutical company’s stock worth $1,983,000 after purchasing an additional 5,551 shares during the last quarter. Murphy & Mullick Capital Management Corp lifted its position in shares of Bristol Myers Squibb by 19.5% in the first quarter. Murphy & Mullick Capital Management Corp now owns 3,954 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 646 shares in the last quarter. Certified Advisory Corp boosted its stake in Bristol Myers Squibb by 14.6% during the first quarter. Certified Advisory Corp now owns 4,684 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 597 shares during the last quarter. Finally, Signal Advisors Wealth LLC boosted its stake in Bristol Myers Squibb by 7.4% during the first quarter. Signal Advisors Wealth LLC now owns 7,852 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 539 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on BMY. HSBC upped their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Bank of America lowered their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Trading Up 1.7%

Shares of BMY opened at $55.61 on Wednesday. The company’s fifty day simple moving average is $57.19 and its 200-day simple moving average is $57.22. The company has a market cap of $113.56 billion, a P/E ratio of 15.62, a P/E/G ratio of 0.16 and a beta of 0.24. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.